Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?

被引：0
|
作者：
Gupta V. [1 ]
Ramirez M.C. [1 ]
Schauser L. [1 ]
机构：
[1] QIAGEN, India
来源：
Genetic Engineering and Biotechnology News | 2019年 / 39卷 / 06期
关键词：
3;
D O I：
10.1089/gen.39.06.19
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：56 / 57
页数：1
相关论文
共 50 条
  • [41] A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
    Song, Congkuan
    Wu, Zhiquan
    Wang, Qingwen
    Wang, Yujin
    Guo, Zixin
    Li, Sheng
    Hu, Weidong
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [42] Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies
    Thawani, Rajat
    Kartika, Thomas
    Elstrott, Benjamin
    Batiuk, Elizabeth
    Tao, Derrick
    Gowda, Sonia
    Chen, Lilian
    Lavasseur, Corinne
    Tun, Nattapron
    Taflin, Nicholas F.
    Shatzel, Joseph
    THROMBOSIS RESEARCH, 2022, 217 : 12 - 14
  • [43] Loss of heterozygosity associates with PD-L1 expression and tumor mutational burden in high-grade endometrial tumors
    Mazina, Varvara
    Rueda, Bo
    Eisenhauer, Eric
    Bregar, Amy
    Philp, Lauren
    Watkins, Jaclyn
    Johnstone, Sarah
    Growdon, Whitfield
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S15 - S15
  • [44] PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
    Baek, M-H.
    Chen, L.
    Jelinic, P.
    Cristescu, R.
    Jin, X. Y.
    Shao, C.
    Tekin, C.
    Park, J-Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S758 - S758
  • [45] Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.
    Gibney, Geoffrey Thomas
    Tang, Shaojun
    Poorman, Kelsey
    Olszanski, Anthony J.
    Eisenberg, Burton Larry
    Mehmi, Inderjit
    Farma, Jeffrey M.
    In, Gino Kim
    Amin, Asim
    Rapisuwon, Suthee
    Vanderwalde, Ari M.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations
    Gagne, Andreanne
    Wang, Emily
    Bastien, Nathalie
    Orain, Michele
    Desmeules, Patrice
    Page, Sylvain
    Trahan, Sylvain
    Couture, Christian
    Joubert, David
    Joubert, Philippe
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : 2062 - 2070
  • [47] Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer
    Baek, Min-Hyun
    Chen, Lei
    Tekin, Cumhur
    Cristescu, Razvan
    Jin, Xiao Yang
    Shao, Changxia
    Ihm, Soo Yeon
    Jelinic, Petar
    Park, Jeong-Yeol
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [48] Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Zang, Yuan-Sheng
    MEDICAL HYPOTHESES, 2018, 116 : 111 - 113
  • [49] ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
    Luchini, C.
    Bibeau, F.
    Ligtenberg, M. J. L.
    Singh, N.
    Nottegar, A.
    Bosse, T.
    Miller, R.
    Riaz, N.
    Douillard, J. -Y.
    Andre, F.
    Scarpa, A.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1232 - 1243
  • [50] Tumor mutational burden for the prediction of PD-(L)1 blockade ef fi cacy in cancer: challenges and opportunities
    Wang, X.
    Lamberti, G.
    Di Federico, A.
    Alessi, J.
    Ferrara, R.
    Sholl, M. L.
    Awad, M. M.
    Vokes, N.
    Ricciuti, B.
    ANNALS OF ONCOLOGY, 2024, 35 (06) : 508 - 522
12345